Pharmaceuticals, Biotechnology & Life Sciences

Explore Puma Biotechnology’s strategy to repurpose early‑stage cancer therapies, its recent Nasdaq rebound, and key investment metrics for 2026.

REGENXBIO’s March 5 2026 conference call will reveal Q4‑2025 earnings, pipeline progress, and strategic plans, offering investors a clear view of its biotech growth.

GuangYuYuan, a leading Xi’an‑based Chinese herbal pharma, delivers diverse medicines and advertising services while its stock shows steady resilience—learn about its recent leadership updates and market position.

Collegium Pharmaceutical’s stock lags its 52‑week high; the biotech’s CNS, respiratory and skin drug pipeline and new Boston Legacy FC partnership offer growth potential amid cautious investor sentiment.

Gilead Sciences expands oncology with Arcellx acquisition and boosts its HIV lineup using a single‑tablet bictegravir‑lenacapavir regimen, positioning it ahead of competitors.

Explore how WuXi AppTec’s robust CMOs/CDMOs platform and advanced proteomics services position it for growth amid a booming contract‑manufacturing market.

Yifan Pharmaceutical, a Lin’an‑based biotech leader, excels in biochemicals, fine chemicals, and technology transfer, driving innovation and growth on the Shenzhen Stock Exchange.

Cadrenal Therapeutics’ Phase 2 success with CAD‑1005 shows promise for treating ESRD‑related thromboembolism, sparking investor interest amid biotech volatility.

ADMA Biologics delivers record FY 2025 revenue and earnings growth, fueled by ASCENIV and a promising SG‑001 pipeline, while disciplined capital strategy drives shareholder value.

InflaRx NV: German biopharma firm advancing monoclonal antibody drugs for inflammatory diseases, with volatile share price yet strong investor confidence and upcoming 2026 investor conference.